The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth

被引:2
|
作者
Qian, Jing [1 ,8 ]
Ma, Yanxia [1 ,7 ]
Tahaney, William M. [1 ,2 ,6 ]
Moyer, Cassandra L. [1 ]
Lanier, Amanda [1 ]
Hill, Jamal [1 ]
Coleman, Darian [1 ]
Koupaei, Negar [1 ,4 ]
Hilsenbeck, Susan G. [3 ]
Savage, Michelle I. [1 ]
Page, Brent D. G. [5 ]
Mazumdar, Abhijit [1 ]
Brown, Powel H. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dan L Duncan Canc Ctr, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX USA
[5] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[6] Monte Rosa Therapeut, Boston, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, UTHealth Houston Grad Sch Biomed Sci, Houston, TX USA
关键词
Phosphatase; Triple-negative breast cancer; Oxidative stress; EXPRESSION;
D O I
10.1186/s13058-024-01778-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal growth factor receptor 2 (HER2). Treatment options for women with TNBC tumors are limited, unlike those with ER-positive tumors that can be treated with hormone therapy, or those with HER2-positive tumors that can be treated with anti-HER2 therapy. Therefore, we have sought to identify novel targeted therapies for TNBC. In this study, we investigated the potential of a novel phosphatase, NUDT5, as a potential therapeutic target for TNBC.MethodsThe mRNA expression levels of NUDT5 in breast cancers were investigated using TCGA and METABRIC (Curtis) datasets. NUDT5 ablation was achieved through siRNA targeting and NUDT5 inhibition with the small molecule inhibitor TH5427. Xenograft TNBC animal models were employed to assess the effect of NUDT5 inhibition on in vivo tumor growth. Proliferation, death, and DNA replication assays were conducted to investigate the cellular biological effects of NUDT5 loss or inhibition. The accumulation of 8-oxo-guanine (8-oxoG) and the induction of gamma H2AX after NUDT5 loss was determined by immunofluorescence staining. The impact of NUDT5 loss on replication fork was assessed by measuring DNA fiber length.ResultsIn this study, we demonstrated the significant role of an overexpressed phosphatase, NUDT5, in regulating oxidative DNA damage in TNBCs. Our findings indicate that loss of NUDT5 results in suppressed growth of TNBC both in vitro and in vivo. This growth inhibition is not attributed to cell death, but rather to the suppression of proliferation. The loss or inhibition of NUDT5 led to an increase in the oxidative DNA lesion 8-oxoG, and triggered the DNA damage response in the nucleus. The interference with DNA replication ultimately inhibited proliferation.ConclusionsNUDT5 plays a crucial role in preventing oxidative DNA damage in TNBC cells. The loss or inhibition of NUDT5 significantly suppresses the growth of TNBCs. These biological and mechanistic studies provide the groundwork for future research and the potential development of NUDT5 inhibitors as a promising therapeutic approach for TNBC patients.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
    Liu, Yuetong
    Hong, Ge
    Mao, Lina
    Su, Zhe
    Liu, Tianjun
    Liu, Hong
    MOLECULES, 2023, 28 (09):
  • [42] Novel immunotherapy approach for metastatic triple-negative breast cancer
    Griffin, Paul
    Jain, Riya
    Le, Sean
    Rajapakse, Kyle
    Miller, Wilson
    Andarawewa, Kumari
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [43] Novel prognostic stromal subtypes in triple-negative breast cancer
    Thompson, Crista
    Saleh, Sadiq M.
    Bertos, Nicholas
    Gigoux, Mathieu
    Gruosso, Tina
    Souleimanova, Margarita
    Zhao, Hong
    Hallett, Michael T.
    Park, Morag
    CANCER RESEARCH, 2016, 76
  • [44] Development of novel combination therapy for triple-negative breast cancer
    Lee, H.
    Lee, K.
    Lee, J.
    Yoon, K.
    Mohammad, A. M.
    Park, H. S.
    Park, J. S.
    Lee, S. -T.
    Sohn, J.
    BREAST, 2019, 44 : S36 - S37
  • [45] ERRβ: Validating a novel target for triple-negative breast cancer
    Fernandez, Aileen I.
    Graham, Garrett
    Gyorffy, Balazs
    Cavalli, Luciane R.
    Riggins, Rebecca B.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [46] Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer
    Davis, Andrew A.
    Gradishar, William J.
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 176 - +
  • [47] Triple-negative breast cancer: Novel therapies and new directions
    Pal, Sumanta Kumar
    Mortimer, Joanne
    MATURITAS, 2009, 63 (04) : 269 - 274
  • [48] The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer
    Zhenbo Tu
    Johannes Schmoellerl
    Odette Mariani
    Yurong Zheng
    Yi Hu
    Anne Vincent-Salomon
    Antoine E. Karnoub
    npj Breast Cancer, 7
  • [49] The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer
    Tu, Zhenbo
    Schmoellerl, Johannes
    Mariani, Odette
    Zheng, Yurong
    Hu, Yi
    Vincent-Salomon, Anne
    Karnoub, Antoine E.
    NPJ BREAST CANCER, 2021, 7 (01)
  • [50] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)